Online inquiry

IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1984MR)

This product GTTS-WQ1984MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PVRL4 gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_030916.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 81607
UniProt ID Q96NY8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1984MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14240MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ11530MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ7312MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ7809MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ14480MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ4468MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ9433MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ7051MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW